Sei Investments Co. Purchases 18,433 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sei Investments Co. lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 2.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 715,372 shares of the medical equipment provider's stock after purchasing an additional 18,433 shares during the quarter. Sei Investments Co. owned about 0.36% of Zimmer Biomet worth $75,565,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Mizuho Securities USA LLC boosted its holdings in shares of Zimmer Biomet by 42.9% in the fourth quarter. Mizuho Securities USA LLC now owns 18,868 shares of the medical equipment provider's stock valued at $1,993,000 after buying an additional 5,662 shares during the period. Sciencast Management LP boosted its stake in Zimmer Biomet by 35.5% in the 4th quarter. Sciencast Management LP now owns 9,131 shares of the medical equipment provider's stock worth $965,000 after purchasing an additional 2,391 shares during the period. Sector Gamma AS increased its holdings in Zimmer Biomet by 29.9% during the 4th quarter. Sector Gamma AS now owns 137,714 shares of the medical equipment provider's stock worth $14,547,000 after purchasing an additional 31,714 shares in the last quarter. Northwest & Ethical Investments L.P. acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $1,934,000. Finally, iA Global Asset Management Inc. lifted its holdings in shares of Zimmer Biomet by 18.2% in the fourth quarter. iA Global Asset Management Inc. now owns 13,026 shares of the medical equipment provider's stock valued at $1,376,000 after purchasing an additional 2,006 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Truist Financial reissued a "hold" rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Raymond James cut their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Royal Bank of Canada cut their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Finally, JMP Securities restated a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of "Hold" and an average target price of $124.15.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.95% of the stock is owned by insiders.

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded down $0.74 during trading hours on Tuesday, hitting $110.50. The company had a trading volume of 847,145 shares, compared to its average volume of 1,496,400. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $133.90. The firm has a market cap of $22.00 billion, a PE ratio of 24.83, a PEG ratio of 1.95 and a beta of 1.04. The firm has a 50-day moving average of $106.86 and a 200 day moving average of $106.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the company posted $2.20 earnings per share. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.87%. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.